...Venture, Abingworth and other undisclosed institutional investors.RA, Vivo lead Kira’s $53.5M series B+ roundCross-border biotech Kira Pharmaceuticals...
...CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA...

...inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway. Kira Pharmaceuticals Ltd....
...– Complement C1r C1s –Complement component 1 s subcomponentC3 – Complement 3C5 – Complement 5 Sandi Wong Kira Pharmaceuticals Ltd. University...

...so far, in companion diagnostics company Qiagen Suzhou Translational Medicine Co. Ltd. and cancer companies Kira Pharmaceuticals Ltd....
...China dMed Co. Ltd., Shanghai, China Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM), Hong Kong, China Kira Pharmaceuticals Ltd....